Last 7 days
2.0%
Last 30 days
3.3%
Last 90 days
-7.6%
Trailing 12 Months
-17.2%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 10.1B | 10.0B | 10.0B | 0 |
2022 | 10.8B | 10.6B | 10.4B | 10.2B |
2021 | 12.6B | 11.7B | 11.1B | 11.0B |
2020 | 14.4B | 14.5B | 14.3B | 13.4B |
2019 | 13.8B | 14.1B | 14.2B | 14.4B |
2018 | 12.6B | 12.9B | 13.2B | 13.5B |
2017 | 11.5B | 11.7B | 11.8B | 12.3B |
2016 | 10.9B | 11.2B | 11.4B | 11.4B |
2015 | 10.1B | 10.3B | 10.6B | 10.8B |
2014 | 7.6B | 8.3B | 9.0B | 9.7B |
2013 | 5.6B | 5.9B | 6.4B | 6.9B |
2012 | 5.1B | 5.3B | 5.4B | 5.5B |
2011 | 4.8B | 4.8B | 4.9B | 5.0B |
2010 | 4.4B | 4.6B | 4.6B | 4.7B |
2009 | 4.2B | 4.3B | 4.3B | 4.4B |
2008 | 3.4B | 3.6B | 3.9B | 4.1B |
2007 | 0 | 0 | 0 | 3.2B |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 05, 2023 | singhal priya | sold | -116,124 | 269 | -431 | head of development |
Sep 01, 2023 | singhal priya | sold (taxes) | -215,606 | 267 | -807 | head of development |
Sep 01, 2023 | mcdonnell michael r | acquired | - | - | 5,285 | evp, chief financial officer |
Sep 01, 2023 | singhal priya | acquired | - | - | 1,668 | head of development |
Sep 01, 2023 | mcdonnell michael r | sold (taxes) | -722,428 | 267 | -2,704 | evp, chief financial officer |
Jul 03, 2023 | singhal priya | sold | -22,912 | 282 | -81.00 | head of development |
Jun 30, 2023 | singhal priya | acquired | - | - | 315 | head of development |
Jun 30, 2023 | kramer robin | acquired | - | - | 252 | chief accounting officer |
Jun 30, 2023 | izzar rachid | acquired | - | - | 504 | head of global product strat. |
Jun 30, 2023 | izzar rachid | sold (taxes) | -69,503 | 284 | -244 | head of global product strat. |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Dec 07, 2023 | Hudson Bay Capital Management LP | added | 186 | 26,027,800 | 42,406,600 | 0.17% |
Dec 06, 2023 | Raleigh Capital Management Inc. | unchanged | - | -696 | 6,425 | -% |
Dec 06, 2023 | CITIGROUP INC | reduced | -5.6 | -9,917,810 | 56,994,000 | 0.04% |
Dec 04, 2023 | Phoenix Holdings Ltd. | sold off | -100 | -617,772 | - | -% |
Dec 04, 2023 | Trust Co | unchanged | - | -4,538 | 41,893 | 0.01% |
Dec 01, 2023 | B. Riley Wealth Advisors, Inc. | reduced | -9.08 | -195,587 | 893,110 | 0.02% |
Dec 01, 2023 | Fortis Group Advisors, LLC | new | - | 3,855 | 3,855 | -% |
Nov 29, 2023 | Carmignac Gestion | reduced | -0.32 | -8,888,660 | 79,442,000 | 1.46% |
Nov 27, 2023 | USA FINANCIAL FORMULAS | added | 0.45 | -227,097 | 2,196,410 | 3.28% |
Nov 27, 2023 | BANQUE PICTET & CIE SA | reduced | -38.99 | -5,042,360 | 6,173,890 | 0.07% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.32% | 11,976,623 | SC 13G/A | |
Feb 09, 2023 | primecap management co/ca/ | 10.9% | 15,700,576 | SC 13G/A | |
Jan 24, 2023 | blackrock inc. | 9.9% | 14,260,137 | SC 13G/A | |
Mar 07, 2022 | blackrock inc. | 9.4% | 13,736,954 | SC 13G/A | |
Feb 10, 2022 | primecap management co/ca/ | 10.73% | 15,757,405 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 7.85% | 11,537,299 | SC 13G/A | |
Feb 08, 2022 | blackrock inc. | 9.4% | 13,736,954 | SC 13G | |
Feb 12, 2021 | primecap management co/ca/ | 10.28% | 15,822,066 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 7.73% | 11,896,510 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 8.7% | 13,419,601 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Nov 08, 2023 | 8-K | Current Report | |
Nov 08, 2023 | 8-K | Current Report | |
Nov 08, 2023 | 10-Q | Quarterly Report | |
Nov 03, 2023 | 4 | Insider Trading | |
Oct 12, 2023 | 3 | Insider Trading | |
Sep 28, 2023 | SC 13D/A | 13D - Major Acquisition | |
Sep 28, 2023 | 8-K/A | Current Report | |
Sep 28, 2023 | 4 | Insider Trading | |
Sep 26, 2023 | 8-K | Current Report | |
Sep 06, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 389.5B | 102.8B | 2.69% | -12.25% | 11.25 | 3.79 | 11.47% | 80.74% |
MRK | 272.8B | 59.3B | -0.63% | -5.14% | 17.88 | 4.63 | 0.58% | -69.80% |
PFE | 162.5B | 68.5B | -6.62% | -44.42% | 15.5 | 2.37 | -31.38% | -64.79% |
AMGN | 144.0B | 26.8B | -1.52% | -4.93% | 19.03 | 5.37 | 1.91% | 10.69% |
GILD | 98.5B | 27.4B | 1.44% | -10.10% | 16.77 | 3.6 | 0.94% | 76.21% |
MID-CAP | ||||||||
TEVA | 11.0B | 15.3B | 7.32% | 18.03% | -4.98 | 0.72 | 0.87% | -71.24% |
ALKS | 4.3B | 1.6B | 4.36% | 1.49% | 20.08 | 2.71 | 40.56% | 266.27% |
PRGO | 4.0B | 4.7B | 2.10% | -7.72% | -978.12 | 0.86 | 5.74% | 96.18% |
AMPH | 2.7B | 601.3M | 24.99% | 94.42% | 20.1 | 4.52 | 24.02% | 75.17% |
BHC | 2.7B | 8.5B | 1.81% | -4.07% | -2.77 | 0.31 | 5.11% | -479.13% |
SMALL-CAP | ||||||||
TLRY | 1.4B | 650.9M | 10.34% | -28.86% | -0.96 | 2.13 | 6.08% | -185.21% |
TXMD | 22.1M | - | -5.00% | -65.05% | 0.32 | 0.55 | -19.54% | 888.31% |
ACOR | 15.2M | 111.1M | 27.41% | 2089.90% | -0.96 | 0.14 | -10.43% | 84.90% |
ACRX | 12.5M | - | 39.62% | -61.05% | -0.59 | 0.13 | 287.27% | -145.15% |
AGRX | 5.2M | 20.0M | 16.16% | 1110.53% | -0.38 | 0.26 | 137.71% | 66.04% |
Income Statement (Quarterly) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | 3.0% | 2,530 | 2,456 | 2,463 | 2,544 | 2,509 | 2,589 | 2,532 | 2,734 | 2,779 | 2,775 | 2,694 | 2,853 | 3,376 | 3,682 | 3,534 | 3,671 | 3,600 | 3,617 | 3,490 | 3,526 | 3,439 |
Costs and Expenses | 52.8% | 2,672 | 1,748 | 2,025 | 1,940 | 1,137 | 1,320 | 2,184 | 2,582 | 2,488 | 2,193 | 1,720 | 2,686 | 2,290 | 1,707 | 1,714 | 1,894 | 1,794 | 1,661 | 1,987 | 2,083 | 1,741 |
S&GA Expenses | 43.8% | 788 | 548 | 605 | 633 | 563 | 573 | 635 | 788 | 654 | 637 | 595 | 806 | 573 | 555 | 570 | 665 | 555 | 588 | 568 | 591 | 498 |
EBITDA Margin | -39.5% | 0.23* | 0.38* | 0.44* | 0.43* | 0.40* | 0.29* | 0.22* | 0.23* | - | - | 0.36* | 0.43* | 0.48* | 0.54* | 0.53* | 0.54* | 0.56* | - | - | - | - |
Interest Expenses | 29.9% | 64.00 | 49.00 | 63.00 | 55.00 | 60.00 | 66.00 | 66.00 | 66.00 | 66.00 | 56.00 | 65.00 | 56.00 | 56.00 | 66.00 | 44.00 | 46.00 | 46.00 | 48.00 | 48.00 | 49.00 | 49.00 |
Income Taxes | -163.5% | -72.90 | 115 | 51.00 | 54.00 | 236 | 217 | 126 | 443 | -25.90 | -409 | 44.00 | 13.00 | 241 | 446 | 292 | 276 | 211 | 248 | 423 | 470 | 370 |
Earnings Before Taxes | -119.9% | -141 | 708 | 438 | 604 | 1,371 | 1,270 | 347 | 405 | 291 | 582 | 467 | 353 | 958 | 2,038 | 1,699 | 1,728 | 1,779 | 1,759 | 1,860 | 1,415 | 1,813 |
EBT Margin | -48.6% | 0.16* | 0.31* | 0.36* | 0.35* | 0.33* | 0.22* | 0.15* | 0.16* | 0.15* | 0.20* | 0.30* | 0.38* | 0.45* | 0.50* | 0.48* | - | - | - | - | - | - |
Net Income | -111.5% | -68.10 | 592 | 388 | 550 | 1,135 | 1,058 | 304 | 368 | 329 | 449 | 410 | 358 | 702 | 1,542 | 1,399 | 1,440 | 1,546 | 1,494 | 1,409 | 947 | 1,444 |
Net Income Margin | -45.3% | 0.15* | 0.27* | 0.31* | 0.30* | 0.28* | 0.19* | 0.13* | 0.14* | 0.14* | 0.16* | 0.24* | 0.30* | 0.36* | 0.41* | 0.41* | - | - | - | - | - | - |
Free Cashflow | 24.6% | 518 | 416 | 389 | -261 | 602 | 700 | 104 | 787 | 763 | 1,155 | 676 | -453 | 1,097 | 1,844 | 1,318 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | 12.1% | 28,193 | 25,157 | 24,598 | 24,554 | 24,854 | 25,081 | 23,614 | 23,877 | 23,807 | 24,470 | 23,855 | 24,619 | 24,934 | 25,512 | 26,119 | 27,234 | 27,484 | 26,288 | 26,446 | 25,289 | 25,492 |
Current Assets | -19.0% | 8,454 | 10,432 | 9,763 | 9,791 | 9,766 | 9,741 | 7,916 | 7,857 | 7,162 | 7,184 | 6,720 | 6,887 | 7,843 | 8,494 | 8,007 | 8,382 | 8,448 | 7,910 | 8,943 | 7,641 | 8,719 |
Cash Equivalents | -12.6% | 2,288 | 2,618 | 2,898 | 3,419 | 3,676 | 2,647 | 1,749 | 2,261 | 1,542 | 1,742 | 1,218 | 1,331 | 2,225 | 2,385 | 2,591 | 2,914 | 2,344 | 1,723 | 2,243 | 1,225 | 2,387 |
Inventory | 123.7% | 2,982 | 1,334 | 1,281 | 1,344 | 1,375 | 1,294 | 1,215 | 1,352 | 1,348 | 1,255 | 1,172 | 1,069 | 1,028 | 953 | 859 | 804 | 752 | 777 | 770 | 930 | 917 |
Net PPE | -0.2% | 3,302 | 3,307 | 3,301 | 3,299 | 3,266 | 3,355 | 3,373 | 3,416 | 3,411 | 3,442 | 3,438 | 3,412 | 3,360 | 3,331 | 3,282 | 3,247 | 3,138 | 3,078 | 3,014 | 3,601 | 3,539 |
Goodwill | 18.3% | 6,808 | 5,754 | 5,752 | 5,749 | 5,741 | 5,750 | 5,758 | 5,761 | 5,761 | 5,764 | 5,763 | 5,762 | 5,756 | 5,751 | 5,752 | 5,758 | 5,746 | 5,749 | 5,640 | 5,706 | 5,440 |
Liabilities | 28.2% | 13,714 | 10,696 | 10,811 | 11,166 | 12,087 | 13,218 | 12,394 | 12,918 | 12,925 | 13,256 | 13,192 | 13,933 | 14,190 | 14,223 | 13,582 | 13,895 | 13,492 | 13,339 | 12,624 | 12,257 | 11,732 |
Current Liabilities | 57.6% | 5,022 | 3,187 | 3,015 | 3,273 | 3,926 | 5,018 | 3,947 | 4,298 | 4,212 | 3,347 | 3,166 | 3,742 | 3,804 | 3,447 | 4,639 | 4,864 | 4,432 | 3,211 | 3,149 | 3,295 | 3,175 |
Long Term Debt | 8.0% | 6,786 | 6,285 | 6,283 | 6,281 | 6,279 | 6,277 | 6,276 | 6,274 | 6,272 | 7,269 | 7,267 | 7,426 | 7,425 | 7,424 | 4,460 | 4,459 | 4,458 | 5,949 | 5,943 | 5,937 | 5,931 |
Shareholder's Equity | 0.1% | 14,480 | 14,467 | 13,787 | 13,398 | 12,776 | 11,863 | 11,221 | 10,960 | 10,882 | 11,215 | 10,663 | 10,686 | 10,745 | 11,289 | 12,537 | 13,339 | 13,992 | 12,949 | 13,822 | 13,032 | 13,767 |
Retained Earnings | -0.4% | 17,378 | 17,446 | 16,854 | 16,467 | 15,916 | 14,960 | 14,216 | 13,912 | 13,544 | 13,901 | 13,834 | 13,976 | 13,961 | 14,467 | 15,673 | 16,455 | 17,065 | 16,183 | 17,027 | 16,257 | 16,944 |
Additional Paid-In Capital | 41.9% | 242 | 171 | 91.00 | 73.00 | - | - | 119 | 68.00 | - | - | - | - | - | - | 0.00 | - | - | - | - | - | 48.00 |
Shares Outstanding | -100.0% | - | 145 | 144 | - | 144 | 146 | 147 | - | 148 | 150 | 152 | 154 | 157 | 161 | 173 | 178 | 184 | 190 | 197 | 200 | 201 |
Minority Interest | 35.9% | -4.10 | -6.40 | -9.60 | -9.50 | -8.70 | -9.10 | -21.60 | 64.00 | 452 | 463 | -19.00 | -14.20 | -14.00 | -19.50 | -10.00 | -4.10 | -4.10 | -4.10 | -7.90 | -8.00 | -6.80 |
Cashflow (Quarterly) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | 21.6% | 592 | 487 | 455 | -175 | 661 | 737 | 162 | 838 | 805 | 1,227 | 769 | -367 | 1,181 | 1,949 | 1,467 | 1,960 | 1,695 | 1,964 | 1,460 | 1,895 | 1,736 |
Share Based Compensation | 12.6% | -64.80 | -74.10 | 76.00 | 189 | -65.70 | -58.00 | 68.00 | 170 | -57.60 | -55.80 | 70.00 | 132 | -35.40 | -49.50 | 68.00 | 139 | -47.80 | -55.00 | 46.00 | 35.00 | 40.00 |
Cashflow From Investing | -131.2% | -1,742 | -753 | -953 | -141 | 1,672 | 694 | -648 | -112 | -233 | -152 | -64.70 | -166 | -52.40 | -832 | 443 | 708 | -365 | -110 | 239 | -1,625 | -619 |
Cashflow From Financing | 8759.2% | 849 | -9.80 | -43.40 | -7.40 | -1,251 | -471 | -16.50 | 10.00 | -746 | -564 | -785 | -401 | -1,312 | -1,313 | -2,245 | -2,116 | -689 | -2,375 | -679 | -1,437 | 25.00 |
Buy Backs | - | - | - | - | - | 250 | 500 | - | - | 750 | 450 | 600 | 400 | 1,250 | 2,809 | 2,220 | 2,093 | 718 | 2,402 | 656 | 1,353 | - |
Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Total revenue | $ 2,530.3 | $ 2,508.5 | $ 7,449.3 | $ 7,629.4 |
Cost and expenses: | ||||
Cost of sales, excluding amortization and impairment of acquired intangible assets | 659.6 | 469.5 | 1,915.1 | 1,707.4 |
Research and development | 736.3 | 549.2 | 1,891.1 | 1,629.5 |
Selling, general and administrative | 788.2 | 563.3 | 1,941.2 | 1,770.8 |
Amortization and impairment of acquired intangible assets | 60.9 | 56.5 | 164.0 | 190.9 |
Collaboration profit sharing/(loss reimbursement) | 50.5 | 45.3 | 164.5 | (42.6) |
(Gain) loss on fair value remeasurement of contingent consideration | 0.0 | (2.1) | 0.0 | (13.7) |
Restructuring charges | 76.0 | 15.4 | 120.0 | 124.1 |
Gain on sale of building | 0.0 | 503.7 | 0.0 | 503.7 |
Other (income) expense, net | 300.0 | (56.0) | 248.2 | (221.3) |
Total cost and expense | 2,671.5 | 1,137.4 | 6,444.1 | 4,641.4 |
Income (loss) before income tax (benefit) expense and equity in loss of investee, net of tax | (141.2) | 1,371.1 | 1,005.2 | 2,988.0 |
Income tax (benefit) expense | (72.9) | 236.2 | 92.6 | 578.5 |
Equity in (income) loss of investee, net of tax | 0.0 | 0.0 | 0.0 | (2.6) |
Net income (loss) | (68.3) | 1,134.9 | 912.6 | 2,412.1 |
Net income (loss) attributable to noncontrolling interests, net of tax | (0.2) | 0.2 | 1.2 | (84.4) |
Net income (loss) attributable to Biogen Inc. | $ (68.1) | $ 1,134.7 | $ 911.4 | $ 2,496.5 |
Net income per share: | ||||
Basic earnings (loss) per share attributable to Biogen Inc. | $ (0.47) | $ 7.86 | $ 6.30 | $ 17.12 |
Diluted earnings (loss) per share attributable to Biogen Inc. | $ (0.47) | $ 7.84 | $ 6.26 | $ 17.07 |
Weighted-average shares used in calculating: | ||||
Basic earnings (loss) per share attributable to Biogen Inc. | 144,800 | 144,400 | 144,700 | 145,800 |
Diluted earnings (loss) per share attributable to Biogen Inc. | 144,800 | 144,800 | 145,500 | 146,200 |
Product, net | ||||
Total revenue | $ 1,805.2 | $ 1,962.1 | $ 5,414.3 | $ 6,083.3 |
LEQEMBI Collaboration | ||||
Cost and expenses: | ||||
Selling, general and administrative | 38.7 | |||
Revenue from anti-CD20 therapeutic programs | ||||
Total revenue | 420.9 | 416.9 | 1,253.8 | 1,252.6 |
Contract manufacturing, royalty and other revenue | ||||
Total revenue | $ 304.2 | $ 129.5 | $ 781.2 | $ 293.5 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 2,287.9 | $ 3,419.3 |
Marketable securities | 0.0 | 1,473.5 |
Inventory | 2,982.4 | 1,344.4 |
Other current assets | 974.1 | 1,417.6 |
Total current assets | 8,454.1 | 9,791.2 |
Marketable securities | 0.1 | 705.7 |
Property, plant and equipment, net | 3,301.6 | 3,298.6 |
Operating lease assets | 460.9 | 403.9 |
Intangible assets, net | 7,344.6 | 1,850.1 |
Goodwill | 6,807.5 | 5,749.0 |
Deferred tax asset | 1,069.8 | 1,226.4 |
Investments and other assets | 754.6 | 1,529.2 |
Total assets | 28,193.2 | 24,554.1 |
Current liabilities: | ||
Current portion of term loan | 500.0 | 0.0 |
Taxes payable | 243.8 | 259.9 |
Accounts payable | 440.1 | 491.5 |
Accrued expense and other | 3,838.4 | 2,521.4 |
Total current liabilities | 5,022.3 | 3,272.8 |
Notes payable and term loan | 6,786.4 | 6,281.0 |
Deferred tax liability | 728.1 | 334.7 |
Long-term operating lease liabilities | 428.8 | 333.0 |
Other long-term liabilities | 747.9 | 944.2 |
Total liabilities | 13,713.5 | 11,165.7 |
Commitments, contingencies and guarantees | ||
Biogen Idec Inc. shareholders' equity | ||
Preferred stock, par value $0.001 per share | 0.0 | 0.0 |
Common stock, par value $0.0005 per share | 0.1 | 0.1 |
Additional paid-in capital | 242.2 | 73.3 |
Accumulated other comprehensive income (loss) | (159.3) | (164.9) |
Retained earnings | 17,377.9 | 16,466.5 |
Treasury stock, at cost | (2,977.1) | (2,977.1) |
Total Biogen Inc. shareholders’ equity | 14,483.8 | 13,397.9 |
Noncontrolling interests | (4.1) | (9.5) |
Total equity | 14,479.7 | 13,388.4 |
Total liabilities and equity | 28,193.2 | 24,554.1 |
Nonrelated Party | ||
Current assets: | ||
Accounts receivable, net | 1,781.4 | 1,705.0 |
Related Party | ||
Current assets: | ||
Accounts receivable, net | $ 428.3 | $ 431.4 |
 CEO | Mr. Christopher A. Viehbacher |
---|---|
 WEBSITE | www.biogen.com |
 EMPLOYEES | 8725 |